AMLo Biosciences

Calling all US-based Dermatology Physician Associates heading off to the #SDPA #derm_pa Conference, this week. Take a look at our recent opinion piece from Karoline Dempsey, Board-Certified Physician Assistant and Diplomate of Dermatology, on using #AMBLor #melanoma prognostic test in clinical practice. The immunohistochemistry-based assay AMBLor identifies two biomarker proteins in the initial skin sample from early-stage melanoma patients and accurately identifies those at low risk of progression. “We know what to do with very aggressive, deep melanomas, and we know what to do with the very thin melanomas,” PA Dempsey says. It’s all the cases in between that make it so difficult to identify the patients at highest risk for aggressive cancer. That’s why novel risk assessment tools are so important for healthcare providers.” With this additional prognostic information from AMBLor, the oncology team can personalise the treatment and follow-up plan. AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. AMBLor has received its UKCA mark in the UK. #dermPAsforDermPAs #dermatology #dermconference #skincancer #oncology #dermatopathology #histopathology #biomarkers

AMLo Biosciences are in the neon city this week attending and exhibiting at the Society of Dermatology Physician Associates #derm_pa Conference, November 13-17, Las Vegas. We are really looking forward to networking with the DermPA delegates and learning about the challenges they’re facing in #melanoma management and patient care. We can be found at booth 203, so do stop by and talk to Alex Pogorzelski and Jennifer Goodman, M.S. about our #melanoma biomarker test #AMBLor that can accurately segment early-stage patients at low risk of disease progression. AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. AMBLor has received its UKCA mark in the UK. #SDPA #dermPAsforDermPAs #dermatology #dermconference #skincancer #oncology

Karoline Dempsey, MPAS, PA-C Board-Certified Physician Assistant and Diplomate of Dermatology has provided her thoughts on #AMBLor in clinical practice, ahead of the Society of Dermatology Physician Associates #derm_pa Conference in Las Vegas later this week. PA Dempsey sees around 30 patients every day and knows that having as much information about a #melanoma at diagnosis is critical for successful outcomes. AMBLor is the prognostic test that identifies the presence or absence of two biomarker proteins. With at least one protein present, patients are less likely to have progressive melanoma. “AMBLor offers more reassurance that we can give to the patients,” PA Dempsey says. “It is nice to say the analysis was done on their particular melanoma, so it gives me a more personalised result to share.” “Everyone worries because melanoma can be so aggressive. I always feel very reassured when I can say, ‘Hey, I have some good news for you.’” She added. Even when the test results are not what was hoped for, the results are passed to the oncologist to support a more informed treatment plan at this early stage of melanoma. For US residents, access the full piece here: https://bit.ly/3O2oO8Z #dermPAsforDermPAs #dermatology #dermconference #skincancer #oncology #dermatopathology #histopathology #biomarkers

Prof Sloan and Dr Akhtar Husain are presenting new research on the use of AMBLor technology in #melanoma in situ, #atypicallesions and #spitznaevi, which we hope will lead to further improvements for clinicians to better manage their patients at American Society of Dermatology #ASDP24.

AMLo Biosciences are delighted to be attending and exhibiting at The Society of Dermatology Physician Associates #derm_pa Conference, November 13-17, Las Vegas. Stop by booth 203 to talk to Alex Pogorzelski and Jen Goodman about our #melanoma prognostic test #AMBLor that can accurately identify a subset of early-stage patients who are at low risk of disease progression. This information can then be used to improve patient management by tailoring further procedures, follow-up and easing anxiety around recurrence. We are very much looking forward to meeting all the specialists working in dermatologic care. AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. AMBLor has received its UKCA mark in the UK. #dermatology #histopathology #oncology #skincancer #biomarkers #cancerresreach #dermatopathology

Just a reminder that Professor Phil Sloan and Dr Akhtar Husain, our leading pathology experts, are in the US attending the American Society of Dermatology Annual Meeting 7-10 November #ASDP24. They would be happy to meet and discuss #AMBLor, our biomarker prognostic that accurately identifies early-stage melanomas at low risk of progression. Find out more about how using this test can personalise melanoma management through effective use of further diagnostic procedures and follow-ups, and help ease patient anxiety. Please message Alex Pogorzelski at inquiries@usa.amlo-biosciences.com to arrange a time to chat. Professor Sloan and Dr Husain are also presenting new research on the use of AMBLor technology in #melanoma in situ, #atypicallesions and #spitznaevi, which we hope will lead to further improvements for clinicians to better manage their patients. AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. #AMBLor has received its UKCA mark in the UK. #dermatology #histopathology #oncology #skincancer #biomarkers #cancerresreach #dermatopathology #PathologyMatters #PathologyAwareness

Did you know? ·      Approx 95% of all clinical pathways rely on patients having access to pathology services. ·      300,000 pathology tests are performed every working day in the UK. ·      50 million reports are sent from labs to GPs every year. This week, The Royal College of Pathologists host National #PathologyWeek, an annual celebration of pathology that highlights the vital contribution pathologists make to healthcare. AMLo Biosciences are proud to play a role in the #dermatopathology of #melanoma with #AMBLor, our biomarker prognostic that identifies early-stage low-risk melanomas. With the additional information from this test, clinicians can make more informed decisions about further invasive procedures, follow-up schedules and offer reassurance to patients around disease progression. AMBLor has received its UKCA mark and is now available to healthcare professionals. https://lnkd.in/evB_--5z #PathologistsAndPatients #dermatology #histopathology #oncology #skincancer #biomarkers #cancerresreach

A paper in the New England Journal of Medicine reported that more than half of patients diagnosed with advanced #melanoma and treated with immunotherapy are surviving for at least 10 years, “with some patients now living long enough that they die from other causes”. https://bit.ly/4evlZZm This is very positive news for late-stage melanoma, however only 15% or fewer patients with early AJCC stage I or II melanomas will go on to develop metastases. Through risk stratification using our prognostic #AMBLor, clinicians can segment early-stage melanomas that are at low risk of progression. This additional prognostic understanding can direct treatment and follow up decisions allowing patients to receive more personalised management. #dermatology #dermatopathology #histopathology #oncology #cancerresearch #biomarkers #skincancer

Attention all #dermpathologists attending the American Society of Dermatology Annual Meeting in Chicago on 7-10 November #ASDP24. If you would like to discuss AMLo Biosciences’ #AMBLor test with two of the original founding pathology experts Professor Phil Sloan and Dr Akhtar Husain, please message Alex Pogorzelski @apogorzelski or inquiries@usa.amlo-biosciences.com to arrange a time to chat. Professor Sloan and Dr Husain are also presenting posters on the use of AMBLor technology in #melanoma in situ, #atypicallesions and #spitznaevi. We are very much looking forward to meeting people and being part of this specialist #dermatopathology event. AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. #AMBLor has received its UKCA mark in the UK. #dermatology #histopathology #oncology #skincancer #biomarkers #cancerresreach Castle Biosciences, Inc.

AMLo Biosciences would like to share this post and highlight the important role that people in the beauty industry can play in the early identification of melanoma. Caught early, #skincancer and #melanoma is much more treatable, so we urge those in the industry to complete training in order to be able to identify skin changes and alert clients to see a doctor.